5,118 Shares in Medtronic PLC $MDT Purchased by Great Diamond Partners LLC

Great Diamond Partners LLC bought a new position in Medtronic PLC (NYSE:MDT) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,118 shares of the medical technology company’s stock, valued at approximately $446,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Miramar Capital LLC grew its stake in Medtronic by 0.6% during the second quarter. Miramar Capital LLC now owns 146,997 shares of the medical technology company’s stock valued at $12,814,000 after acquiring an additional 903 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Medtronic by 51.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,790 shares of the medical technology company’s stock valued at $679,000 after purchasing an additional 2,651 shares during the period. Invesco Ltd. grew its position in shares of Medtronic by 3.9% during the 2nd quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock valued at $1,538,302,000 after purchasing an additional 666,557 shares in the last quarter. 1832 Asset Management L.P. increased its holdings in shares of Medtronic by 1.3% in the second quarter. 1832 Asset Management L.P. now owns 1,884,686 shares of the medical technology company’s stock worth $164,288,000 after purchasing an additional 24,839 shares during the period. Finally, CW Advisors LLC increased its holdings in shares of Medtronic by 39.9% in the second quarter. CW Advisors LLC now owns 80,164 shares of the medical technology company’s stock worth $6,988,000 after purchasing an additional 22,855 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on MDT. Weiss Ratings restated a “buy (b)” rating on shares of Medtronic in a research report on Tuesday. JPMorgan Chase & Co. lifted their price target on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Royal Bank Of Canada upped their price objective on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Wells Fargo & Company raised their target price on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $110.44.

Medtronic Stock Down 0.0%

MDT opened at $101.93 on Friday. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The business’s 50-day moving average price is $96.65 and its 200-day moving average price is $92.08. The company has a market cap of $130.68 billion, a P/E ratio of 27.47, a P/E/G ratio of 2.69 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s payout ratio is presently 76.55%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.